Virginia Powers, PhD

Articles

Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval

October 9th 2016

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.

Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib

October 8th 2016

The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.

First-Line Cetuximab Combo Validated in RAS Wild-Type Colorectal Cancer

July 3rd 2016

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.

MABp1 Improves Symptoms in Phase III CRC Study

July 3rd 2016

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

Nivolumab Spurs Encouraging Responses in Metastatic Anal Cancer

July 2nd 2016

The first prospective study to investigate the use of immunotherapy in patients with squamous cell carcinoma of the anal canal demonstrated promising results following treatment with nivolumab.

SIRT Improves Depth of Response in mCRC Patients With Liver Mets

July 1st 2016

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

Adding IMAB362 to Chemo Extends Survival in Advanced Gastric Cancer

July 1st 2016

IMAB362, a novel chimeric IgG1 backbone antibody highly specific for CLDN18.2, extended median overall survival by 4.8 months when added to standard chemotherapy in patients with advanced gastric cancer.

Higher Cytokine Levels Improve Nivolumab Efficacy in Squamous NSCLC

April 16th 2016

Efficacy and safety remained strong 2 years following treatment with nivolumab for patients with advanced, refractory, squamous non-small–cell lung cancer, with an indication that cytokine levels could predict long-term outcomes.

Update Identifies Best Responders to Necitumumab in NSCLC

April 15th 2016

Adding necitumumab to conventional chemotherapy improved outcomes in patients with metastatic squamous non–small cell lung cancer in the phase III SQUIRE trial, but the greatest benefit was derived by patients with EGFR-expressing tumors.

High Response Rates Observed With BI-1482694 in T790M+ NSCLC

April 14th 2016

Patients with non-small cell lung cancer who had ceased to respond to EGFR TKI therapy demonstrated a rapid and robust response to the investigational agent BI-1482694 (HM61713).

Checkpoint Inhibitors Generate Renewed Excitement in RCC

November 18th 2015

With several novel therapies approaching regulatory approval, the treatment landscape for renal cell carcinoma is facing a major upheaval.

ADT Plus Chemo Ideal for Oligometastatic Prostate Cancer

November 17th 2015

Oligometastatic prostate cancer is optimally treated with the combination of docetaxel and androgen deprivation therapy.

Promising Immunotherapy Agents on Horizon in Bladder Cancer

November 16th 2015

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

Factors Identified for Improved Survival With Radium-223

November 13th 2015

Researchers are starting to understand which patients with castration-resistant prostate cancer (CRPC) may benefit most from treatment with radium-223.

Erlotinib/Bevacizumab Effective in EGFR T790M-Mutant NSCLC

September 29th 2015

Treatment with the frontline combination of erlotinib and bevacizumab was highly effective in patients with advanced non–small cell lung cancer who harbored an EGFR T790M mutation.

Fosaprepitant Improves Emesis Control in Women Receiving Chemoradiotherapy for Cervical Cancer

September 28th 2015

Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.

Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma

September 27th 2015

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

Two Pivotal Studies Show Efficacy of Atezolizumab in PD-L1-Positive NSCLC

September 27th 2015

Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.

Targeted Radionuclide Improves PFS Over Octreotide LAR in Midgut NETs

September 26th 2015

Treatment with the novel peptide receptor radionuclide therapy Lutathera significantly increased progression-free survival over octreotide LAR in patients with advanced midgut neuroendocrine tumors.

Everolimus May Be New Standard of Care in Advanced Lung, GI NETs

September 26th 2015

Treatment with everolimus was associated with a 52% improvement in median progression-free survival compared with placebo in patients with advanced lung and gastrointestinal neuroendocrine tumors.